DOI: 10.1002/cia2.12222

CORRESPONDENCE





Linear lichen planus in the lines of Blaschko suggestive of immune-related adverse event

Dear Editor,

Lichen planus (LP) is a mucocutaneous inflammatory disease with a polygenic background.¹ The cutaneous lesions in LP consist of faint erythematous to violaceous flat-topped papules, preferentially involving the extremities, with a bilaterally symmetrical distribution.¹ Linear LP (LLP), a variant of LP, occurs more often in children and adolescents.¹ Although scattered linear lesions often occur in LP, as in the Koebner phenomenon,¹ LLP lesions generally appear as more extensive unilateral streaks or bands.² LLP occasionally follows the lines of Blaschko, which may represent embryological developmental pathways.² Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway blockade-associated cutaneous immune-related adverse events (irAEs) can manifest as lichenoid reactions³; however, the linear variant has rarely been reported. Here, we report a possible case of PD-1 blockade-induced LLP in the lines of Blaschko in a patient with advanced lung cancer.

A 79-year-old Japanese woman was diagnosed with advanced lung adenocarcinoma (Stage IV), and treatment with carboplatin, pemetrexed, and pembrolizumab every four weeks was initiated. She achieved complete remission after six cycles of treatment. However, she developed drug-induced hepatitis, and maintenance therapy with pemetrexed every three weeks was initiated three months later. After the fourth cycle, she developed a skin eruption on the right upper limb (Figure 1A). Physical examination showed linear violaceous macules following the lines of Blaschko on her right upper limb and faint erythematous macules on her right breast (Figure 1B-D). Skin biopsy revealed hyperkeratosis, hypergranulosis, basal liquefaction, Civatte body formation, and a lichenoid inflammatory infiltrate (Figure 1E, F), confirming the histopathological diagnosis of lichenoid reaction. She had no mucocutaneous manifestations suggestive of LP elsewhere. Laboratory tests, including serological tests for hepatitis C, were negative. Although pemetrexed was continued, topical corticosteroids treatment improved the skin lesions after three months.

In our case, the patient developed LLP approximately six months after discontinuing pembrolizumab. Although irAEs usually develop within the first few weeks to months after initiation of the treatment, they can occur even after discontinuation of the treatment.⁴ The median interval for developing irAEs after discontinuing immune checkpoint inhibitors is 6 months (range, 3–28 months).⁴ Therefore, we reasoned that pembrolizumab could have evoked the lichenoid reaction. However, we should acknowledge the possibility of pemetrexed-induced cutaneous adverse event.⁵

The distribution of the lines of Blaschko represents the mosaicism of keratinocytes⁶; that is, the development of LLP following the lines of Blaschko may be predetermined during embryogenesis with the formation of susceptible keratinocytes and is subsequently caused by potential triggers.⁶ In our case, PD-1 blockade may have augmented the CD8⁺ T cell-mediated autoimmune reaction, a hallmark of lichenoid reactions,¹ in predisposed lesions.

Our case may highlight a new aspect of cutaneous mosaicism, in which skin manifestations would become apparent as a form of an irAE. In accordance with the previous report on lichenoid reactions presenting as irAEs,³ we demonstrated that LLP as an irAE can be managed with topical corticosteroids. Further molecular-based approaches would be useful to clarify the detailed pathogenesis.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

^{© 2021} The Authors. Journal of Cutaneous Immunology and Allergy published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society for Cutaneous Immunology and Allergy.




FIGURE 1 Clinical and pathological findings. (A) Graphical representation of the patient's clinical course. (B, C) Unilateral linear violaceous macules along the lines of Blaschko on her right forearm and upper arm, and faint erythematous macules on her right breast (arrow). (D) Close-up of the eruption. (E) Hematoxylin and eosin staining showed hyperkeratosis, hypergranulosis, a band-like infiltrate consisting primarily of lymphocytes in the upper dermis and (F) vacuolar degeneration along the dermoepidermal junction with apoptotic keratinocytes. Bars represent 200 (E) and 50 μm (F). CBDCA, carboplatin; PEM, pemetrexed; Pem, pembrolizumab; Q3W, once every 3 weeks; Q4W, once every 4 weeks

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

DECLARATION SECTION

Approval of the research protocol: N/A. Informed consent: The patient diagnosed at Tsukuba University Hospital was included in this study with written informed consent. Registry and the registration no: N/A. Animal studies: N/A.

> Tatsuya Ogawa MD, PhD¹ Urara Aitake MD¹ Masashi Matsuyama MD, PhD²

Nobuyuki Hizawa MD, PhD² Toshifumi Nomura MD, PhD¹

¹Department of Dermatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan ²Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan

Correspondence

Tatsuya Ogawa, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. Email: ogawa.tatsuya.hp@ms.hosp.tsukuba.ac.jp

ORCID

Tatsuya Ogawa D https://orcid.org/0000-0003-1124-4572

REFERENCES

- 1. Boyd AS, Neldner KH. Lichen planus. J Am Acad Dermatol. 1991;25:593-619.
- Bolognia JL, Orlow SJ, Glick SA. Lines of blaschko. J Am Acad Dermatol. 1994;31:157-90.
- Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and antiprogrammed cell death ligand 1 immunotherapy. JAMA Dermatol. 2016;152:1128–36.
- Couey MA, Bell RB, Patel AA, Romba MC, Crittenden MR, Curti BD, et al. Delayed immune-related events (DIRE) after discontinuation

of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer. 2019;7:165.

- Eguia B, Ruppert A-M, Fillon J, Lavolé A, Gounant V, Epaud C, et al. Skin toxicities compromise prolonged pemetrexed treatment. J Thorac Oncol. 2011;6:2083–9.
- 6. Biesecker LG, Spinner NB. A genomic view of mosaicism and human disease. Nat Rev Genet. 2013;14:307–20.

How to cite this article: Ogawa T, Aitake U, Matsuyama M, Hizawa N, Nomura T. Linear lichen planus in the lines of Blaschko suggestive of immune-related adverse event. J Cutan Immunol Allergy. 2022;5:109–111. <u>https://doi.org/10.1002/</u> cia2.12222